• Positive cash flows from operations of NZ$1.2 million during the quarter
• Total revenue guidance for FY25 of NZ$81-84 million, up 17-22% on FY24
• Normalised EBITDA profit guidance of NZ$2-4 million for FY25

Aroa Biosurgery Limited (ASX: ARX) has reported positive cash flows from operations of NZ$1.2 million during the quarter ended 30 September 2024, reflecting strong receipts from customers of NZ$19.5 million and decreased clinical expenses. The company's total cash on hand increased by NZ$0.3 million, ending the quarter with a strong cash balance of NZ$21.9 million. For the full year FY25, Aroa is guiding for total revenue of NZ$81-84 million, representing a 17-22% increase on FY24. The company also expects to achieve a normalised EBITDA profit of NZ$2-4 million for FY25. This guidance reflects an expected average NZ$/US$ exchange rate of 0.60 for the year.The company highlighted the publication of a peer-reviewed real-world study on the efficacy of its Myriad Matrix and Myriad Morcells products in complex limb salvage procedures. The study found these products achieved successful tissue coverage and fill within 30 days with just one application and no complications. Aroa's direct sales in the US now contribute 56% of the year-to-date sales mix, with the high-margin Myriad family of products continuing to see strong growth of 46% year-on-year. The company also received regulatory approvals to sell its products in new markets during the quarter.

Total revenue of NZ$81-84 million and normalised EBITDA profit of NZ$2-4 million for the full year FY25.

Aroa expects to see positive cash flows continue, driven by strong sales growth, as the company advances towards profitability at the close of FY25.